Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason, and a low valuation can reflect underlying business challenges rather than a genuine bargain.

Identifying genuine bargains from value traps is something many investors struggle with, which is why we started StockStory - to help you find the best companies. Keeping that in mind, here is one value stock trading at a big discount to its intrinsic value and two with little support.

Two Value Stocks to Sell:

Evolent Health (EVH)

Forward P/E Ratio: 13.1x

Founded in 2011 to transform how healthcare is delivered to patients with complex needs, Evolent Health (NYSE: EVH) provides specialty care management services and technology solutions that help health plans and providers deliver better care for patients with complex conditions.

Why Do We Think Twice About EVH?

1. Underwhelming average lives on platform over the past two years indicate demand is soft and that the company may need to revise its strategy
2. Diminishing returns on capital from an already low starting point show that neither management’s prior nor current bets are going as planned
3. High net-debt-to-EBITDA ratio of 7× increases the risk of forced asset sales or dilutive financing if operational performance weakens

Evolent Health’s stock price of $4.50 implies a valuation ratio of 13.1x forward P/E. Check out our free in-depth research report to learn more about why EVH doesn’t pass our bar.

Valaris (VAL)

Forward P/E Ratio: 14.1x

Operating the world's largest fleet of offshore drilling rigs across six continents, Valaris (NYSE: VAL) provides offshore drilling rigs and crews to oil and gas companies exploring and producing in deep waters and shallow seas.

Why Are We Hesitant About VAL?

1. Products and services are facing significant end-market challenges during this cycle as sales have declined by 5% annually over the last ten years
2. High extraction costs and unfavorable asset economics are reflected in its low gross margin of 21.5%
3. Cash burn makes us question whether it can achieve sustainable long-term growth

Valaris is trading at $86.40 per share, or 14.1x forward P/E. Read our free research report to see why you should think twice about including VAL in your portfolio.

One Value Stock to Watch:

MediaAlpha (MAX)

Forward P/E Ratio: 9.9x

Powering nearly 10 million consumer referrals each month in the insurance marketplace, MediaAlpha (NYSE: MAX) operates a technology platform that connects insurance carriers with high-intent consumers shopping for property, casualty, health, and life insurance products.

Why Could MAX Be a Winner?

1. Market share has increased this cycle as its 57% annual revenue growth over the last two years was exceptional
2. Adjusted operating profits increased over the last five years as the company gained some leverage on its fixed costs and became more efficient
3. Earnings growth has massively outpaced its peers over the last two years as its EPS has compounded at 171% annually

At $12.63 per share, MediaAlpha trades at 9.9x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.

High-Quality Stocks for All Market Conditions

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.